Brad Kahl, MD, discusses the treatment options for patients with indolent lymphomas who are relapsed/refractory.
Brad Kahl, MD
Advertisement
Articles by Brad Kahl, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Updated HARMONi Analysis Shows Consistent OS Benefit With Ivonescimab in EGFRm Lung Cancer
2
FDA Accepts NDA for Daraxonrasib in Metastatic Pancreatic Cancer
3
Community Clinical Trials and the Lung Cancer Pipeline
4
How Inherited BRCA Mutations Shape Breast Cancer's Genomic Behavior and Point Toward a New Treatment Paradigm
5